Sanofi recently announced that its respiratory syncytial virus (RSV) preventive treatment, Beyfortus, significantly reduced hospitalizations among infants in two RSV seasons. A study published in The...
Sanofi’s Tzield has been accepted for priority review by the U.S. Food and Drug Administration (FDA) for use in young children diagnosed with stage 2 type...
Sanofi has announced its acquisition of Dynavax Technologies for $15.50 per share, a deal that values the biotechnology company at approximately $2.2 billion. This purchase represents...
U.S. stock markets experienced a substantial rally during the week ending November 24, 2023, buoyed by strong performances from major healthcare companies, including Sanofi, Eli Lilly,...
U.S. stock markets experienced a notable rally during the trading week ending November 24, 2023, buoyed by strong performances from major healthcare companies such as Sanofi,...
Sanofi, a leading French pharmaceutical company, has announced an extension of its partnership with Medidata, a provider of software as a service (SaaS) solutions for the...
